GlassScriptPhysician profile
Daniel R Hartman
NPI 1922241959
$9,295.89
in general payments reported to CMS, 2019-2025
53 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,711 · 2020: $1,196 · 2021: $1,358 · 2022: $1,553 · 2023: $2,189 · 2024: $1,028 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,387 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,387.45 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,701.63 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $894.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $646.25 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $592.70 | 2020-2024 | |
| Amgen INC. | $542.19 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $530.16 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $340.05 | 2019-2023 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $308.93 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $283.77 | 2019-2024 | Xarelto, Spravato |
| Astellas Pharma US INC | $278.03 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $238.99 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $230.07 | 2024-2025 | Xyosted |
| Sanofi-Aventis U.S. LLC | $192.45 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $188.95 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.03 | 2019-2023 | Ofev |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hartman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.